Xeris Biopharma Holdings (XERS) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Xeris Biopharma Holdings (XERS) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 71.83% |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | -0.17% |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | -14.68% |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | -90.23% |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 2,405.06% |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | -14.93% |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 62.34% |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -286.15% |
| 10 | Xeris Biopharma Holdings | 1.15 Bn | 1.04 Bn | 72.55 Mn | 124.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 124.23% |
| Dec 31, 2025 | 316.72% |
| Sep 30, 2025 | 103.95% |
| Jun 30, 2025 | 87.15% |
| Mar 31, 2025 | 51.42% |
| Dec 31, 2024 | 61.81% |
| Sep 30, 2024 | -29.12% |
| Jun 30, 2024 | 24.38% |
| Mar 31, 2024 | -12.75% |
| Dec 31, 2023 | -3.56% |
| Sep 30, 2023 | 44.17% |
| Jun 30, 2023 | 24.22% |
| Mar 31, 2023 | 50.07% |
| Dec 31, 2022 | 74.54% |
| Sep 30, 2022 | 16.06% |
| Jun 30, 2022 | 4.83% |
| Mar 31, 2022 | -83.12% |
| Dec 31, 2021 | -132.37% |
| Sep 30, 2021 | -62.56% |